Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

APOEε4 potentiates the relationship between amyloid-β and tau pathologies.

Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Savard M, Chamoun M, Thomas E, Kang MS, Lussier F, Tissot C, Soucy JP, Massarweh G, Rej S, Saha-Chaudhuri P, Poirier J, Gauthier S, Rosa-Neto P; Alzheimer’s Disease Neuroimaging Initiative.

Mol Psychiatry. 2020 Mar 11. doi: 10.1038/s41380-020-0688-6. [Epub ahead of print]

PMID:
32161362
2.

Guidelines for the content and format of PET brain data in publications and archives: A consensus paper.

Knudsen GM, Ganz M, Appelhoff S, Boellaard R, Bormans G, Carson RE, Catana C, Doudet D, Gee AD, Greve DN, Gunn RN, Halldin C, Herscovitch P, Huang H, Keller SH, Lammertsma AA, Lanzenberger R, Liow JS, Lohith TG, Lubberink M, Lyoo CH, Mann JJ, Matheson GJ, Nichols TE, Nørgaard M, Ogden T, Parsey R, Pike VW, Price J, Rizzo G, Rosa-Neto P, Schain M, Scott PJ, Searle G, Slifstein M, Suhara T, Talbot PS, Thomas A, Veronese M, Wong DF, Yaqub M, Zanderigo F, Zoghbi S, Innis RB.

J Cereb Blood Flow Metab. 2020 Feb 16:271678X20905433. doi: 10.1177/0271678X20905433. [Epub ahead of print] No abstract available.

PMID:
32065076
3.

Morphometric network differences in ageing versus Alzheimer's disease dementia.

Pichet Binette A, Gonneaud J, Vogel JW, La Joie R, Rosa-Neto P, Collins DL, Poirier J, Breitner JCS, Villeneuve S, Vachon-Presseau E; Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD Research Group.

Brain. 2020 Feb 1;143(2):635-649. doi: 10.1093/brain/awz414.

PMID:
32040564
4.

PET Imaging of Perceptual Learning-Induced Changes in the Aged Rodent Cholinergic System.

Cisneros-Franco JM, Voss P, Kang MS, Thomas ME, Côté J, Ross K, Gaudreau P, Rudko DA, Rosa-Neto P, de-Villers-Sidani É.

Front Neurosci. 2020 Jan 21;13:1438. doi: 10.3389/fnins.2019.01438. eCollection 2019.

5.

Association of Vascular Risk Factors With β-Amyloid Peptide and Tau Burdens in Cognitively Unimpaired Individuals and Its Interaction With Vascular Medication Use.

Köbe T, Gonneaud J, Pichet Binette A, Meyer PF, McSweeney M, Rosa-Neto P, Breitner JCS, Poirier J, Villeneuve S; Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) Research Group.

JAMA Netw Open. 2020 Feb 5;3(2):e1920780. doi: 10.1001/jamanetworkopen.2019.20780.

6.

Intermediate flortaucipir uptake is associated with Aβ-PET and CSF tau in asymptomatic adults.

McSweeney M, Pichet Binette A, Meyer PF, Gonneaud J, Bedetti C, Ozlen H, Labonté A, Rosa-Neto P, Breitner J, Poirier J, Villeneuve S; PREVENT-AD Research Group.

Neurology. 2020 Mar 17;94(11):e1190-e1200. doi: 10.1212/WNL.0000000000008905. Epub 2020 Feb 3.

PMID:
32015176
7.

Dynamic 1 H-MRS for detection of 13 C-labeled glucose metabolism in the human brain at 3T.

Dehghani M, Zhang S, Kumaragamage C, Rosa-Neto P, Near J.

Magn Reson Med. 2020 Jan 31. doi: 10.1002/mrm.28188. [Epub ahead of print]

PMID:
32003052
8.

Efficient radiosynthesis and preclinical evaluation of [18 F]FOMPyD as a positron emission tomography tracer candidate for TrkB/C receptor imaging.

Singleton TA, Bdair H, Bailey JJ, Choi S, Aliaga A, Rosa-Neto P, Schirrmacher R, Bernard-Gauthier V, Kostikov A.

J Labelled Comp Radiopharm. 2020 Mar;63(3):144-150. doi: 10.1002/jlcr.3827. Epub 2020 Jan 29.

PMID:
31919878
9.

Mild behavioral impairment is associated with β-amyloid but not tau or neurodegeneration in cognitively intact elderly individuals.

Lussier FZ, Pascoal TA, Chamoun M, Therriault J, Tissot C, Savard M, Kang MS, Mathotaarachchi S, Benedet AL, Parsons M, Qureshi MNI, Thomas ÉM, Shin M, Dion LA, Massarweh G, Soucy JP, Tsai IH, Vitali P, Ismail Z, Rosa-Neto P, Gauthier S.

Alzheimers Dement. 2020 Jan;16(1):192-199. doi: 10.1002/alz.12007.

10.

Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.

Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Chamoun M, Savard M, Thomas E, Kang MS, Lussier F, Tissot C, Parsons M, Qureshi MNI, Vitali P, Massarweh G, Soucy JP, Rej S, Saha-Chaudhuri P, Gauthier S, Rosa-Neto P.

JAMA Neurol. 2019 Dec 20. doi: 10.1001/jamaneurol.2019.4421. [Epub ahead of print]

11.

Brain Metabolic Dysfunction in Early Neuropsychiatric Symptoms of Dementia.

Ng KP, Chiew HJ, Rosa-Neto P, Kandiah N, Ismail Z, Gauthier S.

Front Pharmacol. 2019 Nov 22;10:1398. doi: 10.3389/fphar.2019.01398. eCollection 2019. Review.

12.

Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy.

Ng KP, Therriault J, Kang MS, Struyfs H, Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Massarweh G, Soucy JP, Rosa-Neto P, Gauthier S.

Neuroimage Clin. 2019;24:102091. doi: 10.1016/j.nicl.2019.102091. Epub 2019 Nov 13.

13.

Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images.

Sharafi SM, Sylvestre JP, Chevrefils C, Soucy JP, Beaulieu S, Pascoal TA, Arbour JD, Rhéaume MA, Robillard A, Chayer C, Rosa-Neto P, Mathotaarachchi SS, Nasreddine ZS, Gauthier S, Lesage F.

Alzheimers Dement (N Y). 2019 Oct 14;5:610-617. doi: 10.1016/j.trci.2019.09.006. eCollection 2019.

14.

Suicidal ideation is common in autosomal dominant Alzheimer's disease at-risk persons.

Ng KP, Richard-Devantoy S, Bertrand JA, Jiang L, Pascoal TA, Mathotaarachchi S, Therriault J, Yatawara C, Kandiah N, Greenwood CMT, Rosa-Neto P, Gauthier S; Dominantly Inherited Alzheimer Network.

Int J Geriatr Psychiatry. 2020 Jan;35(1):60-68. doi: 10.1002/gps.5215. Epub 2019 Oct 22.

PMID:
31642105
15.

Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease.

Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Lesage F, Sylvestre JP, Rosa-Neto P, Mathotaarachchi S, Gauthier S, Nasreddine ZS, Arbour JD, Rhéaume MA, Beaulieu S, Dirani M, Nguyen CTO, Bui BV, Williamson R, Crowston JG, van Wijngaarden P.

Nat Commun. 2019 Sep 17;10(1):4227. doi: 10.1038/s41467-019-12242-1.

16.

Inferior Longitudinal Fasciculus' Role in Visual Processing and Language Comprehension: A Combined MEG-DTI Study.

Shin J, Rowley J, Chowdhury R, Jolicoeur P, Klein D, Grova C, Rosa-Neto P, Kobayashi E.

Front Neurosci. 2019 Aug 23;13:875. doi: 10.3389/fnins.2019.00875. eCollection 2019.

17.

Consequences of Metabolic Disruption in Alzheimer's Disease Pathology.

Ryu JC, Zimmer ER, Rosa-Neto P, Yoon SO.

Neurotherapeutics. 2019 Jul;16(3):600-610. doi: 10.1007/s13311-019-00755-y. Review.

PMID:
31270743
18.

Reliability and Validity of the Chinese Version of the Mild Behavioral Impairment Checklist for Screening for Alzheimer's Disease.

Cui Y, Dai S, Miao Z, Zhong Y, Liu Y, Liu L, Jing D, Bai Y, Kong Y, Sun W, Li F, Guo Q, Rosa-Neto P, Gauthier S, Wu L.

J Alzheimers Dis. 2019;70(3):747-756. doi: 10.3233/JAD-190113.

PMID:
31256131
19.

Rostral-Caudal Hippocampal Functional Convergence Is Reduced Across the Alzheimer's Disease Spectrum.

Therriault J, Wang S, Mathotaarachchi S, Pascoal TA, Parent M, Beaudry T, Shin M, Al B, Kang MS, Ng KP, Dansereau C, Park MTM, Fonov V, Carbonell F, Zimmer E, Chakravarty MM, Bellec P, Gauthier S, Rosa-Neto P; Alzheimer’s Disease Neuroimaging Initiative.

Mol Neurobiol. 2019 Dec;56(12):8336-8344. doi: 10.1007/s12035-019-01671-0. Epub 2019 Jun 22.

PMID:
31230260
20.

No apparent effect of naproxen on CSF markers of innate immune activation.

Meyer PF, Labonté A, Rosa-Neto P, Poirier J, Breitner JCS; PREVENT‐AD Research Group.

Ann Clin Transl Neurol. 2019 Jun 6;6(6):1127-1133. doi: 10.1002/acn3.788. eCollection 2019 Jun.

21.

Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation.

Miron J, Picard C, Lafaille-Magnan MÉ, Savard M, Labonté A, Breitner J, Rosa-Neto P, Auld D, Poirier J; PREVENT-AD research group.

Alzheimers Dement. 2019 Jul;15(7):951-960. doi: 10.1016/j.jalz.2019.03.012. Epub 2019 Jun 4.

PMID:
31175027
22.

Aβ-induced vulnerability propagates via the brain's default mode network.

Pascoal TA, Mathotaarachchi S, Kang MS, Mohaddes S, Shin M, Park AY, Parent MJ, Benedet AL, Chamoun M, Therriault J, Hwang H, Cuello AC, Misic B, Soucy JP, Aston JAD, Gauthier S, Rosa-Neto P.

Nat Commun. 2019 Jun 4;10(1):2353. doi: 10.1038/s41467-019-10217-w.

23.

Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression.

Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, Hancock MA, van der Flier WM, Kunach P, Rosa-Neto P, Scheltens P, Poirier J, Saftig P, Bateman RJ, Breitner J, Hock C, Multhaup G.

Nat Commun. 2019 May 20;10(1):2240. doi: 10.1038/s41467-019-10152-w.

24.

First-in-Human Brain Imaging of [18F]TRACK, a PET tracer for Tropomyosin Receptor Kinases.

Bailey JJ, Kaiser L, Lindner S, Wüst M, Thiel A, Soucy JP, Rosa-Neto P, Scott PJH, Unterrainer M, Kaplan DR, Wängler C, Wängler B, Bartenstein P, Bernard-Gauthier V, Schirrmacher R.

ACS Chem Neurosci. 2019 Jun 19;10(6):2697-2702. doi: 10.1021/acschemneuro.9b00144. Epub 2019 Apr 29.

PMID:
31017386
25.

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.

Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER, Tainta M, Izaguirre A, Reijs BLR, Farotti L, Tsolaki M, Vandenbergue R, Freund-Levi Y, Verhey FRJ, Clarimón J, Fortea J, Frolich L, Santana I, Molinuevo JL, Lehmann S, Visser PJ, Teunissen CE, Zetterberg H, Blennow K.

Alzheimers Dement. 2019 Jun;15(6):742-753. doi: 10.1016/j.jalz.2019.01.015. Epub 2019 Apr 6.

PMID:
30967340
26.

INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.

Meyer PF, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Maignan MÉ, Savard M, Rosa-Neto P, Poirier J, Etienne P, Breitner J; PREVENT-AD Research Group.

Neurology. 2019 Apr 30;92(18):e2070-e2080. doi: 10.1212/WNL.0000000000007232. Epub 2019 Apr 5. Erratum in: Neurology. 2019 Aug 20;93(8):371.

27.

PET imaging of freely moving interacting rats.

Miranda A, Kang MS, Blinder S, Bouhachi R, Soucy JP, Aliaga-Aliaga A, Massarweh G, Stroobants S, Staelens S, Rosa-Neto P, Verhaeghe J.

Neuroimage. 2019 May 1;191:560-567. doi: 10.1016/j.neuroimage.2019.02.064. Epub 2019 Mar 2.

28.

Diagnostic Approach of Early-Onset Dementia with Negative Family History: Implications from Two Cases of Early-Onset Alzheimer's Disease with De Novo PSEN1 Mutation.

Liu J, Wang Q, Jing D, Gao R, Zhang J, Cui C, Qiao H, Liang Z, Wang C, Rosa-Neto P, Wu L, Jia J, Gauthier S.

J Alzheimers Dis. 2019;68(2):551-558. doi: 10.3233/JAD-181108.

PMID:
30814350
29.

Cholinergic Potentiation Alters Perceptual Eye Dominance Plasticity Induced by a Few Hours of Monocular Patching in Adults.

Sheynin Y, Chamoun M, Baldwin AS, Rosa-Neto P, Hess RF, Vaucher E.

Front Neurosci. 2019 Jan 31;13:22. doi: 10.3389/fnins.2019.00022. eCollection 2019.

30.

Machine Learning in Nuclear Medicine: Part 1-Introduction.

Uribe CF, Mathotaarachchi S, Gaudet V, Smith KC, Rosa-Neto P, Bénard F, Black SE, Zukotynski K.

J Nucl Med. 2019 Apr;60(4):451-458. doi: 10.2967/jnumed.118.223495. Epub 2019 Feb 7. Review.

PMID:
30733322
31.

Constrained instruments and their application to Mendelian randomization with pleiotropy.

Jiang L, Oualkacha K, Didelez V, Ciampi A, Rosa-Neto P, Benedet AL, Mathotaarachchi S, Richards JB, Greenwood CMT; Alzheimer’s Disease Neuroimaging Initiative.

Genet Epidemiol. 2019 Jun;43(4):373-401. doi: 10.1002/gepi.22184. Epub 2019 Jan 12.

32.

Astrocyte Biomarkers in Alzheimer's Disease.

Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER.

Trends Mol Med. 2019 Feb;25(2):77-95. doi: 10.1016/j.molmed.2018.11.006. Epub 2019 Jan 2. Review.

PMID:
30611668
33.

Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging.

Schirrmacher R, Bailey JJ, Mossine AV, Scott PJH, Kaiser L, Bartenstein P, Lindner S, Kaplan DR, Kostikov A, Fricker G, Mahringer A, Rosa-Neto P, Schirrmacher E, Wängler C, Wängler B, Thiel A, Soucy JP, Bernard-Gauthier V.

Pharmaceuticals (Basel). 2019 Jan 3;12(1). pii: E7. doi: 10.3390/ph12010007. Review.

34.

In vivo metabotropic glutamate receptor type 5 abnormalities localize the epileptogenic zone in mesial temporal lobe epilepsy.

Lam J, DuBois JM, Rowley J, González-Otárula KA, Soucy JP, Massarweh G, Hall JA, Guiot MC, Rosa-Neto P, Kobayashi E.

Ann Neurol. 2019 Feb;85(2):218-228. doi: 10.1002/ana.25404. Epub 2019 Jan 20.

PMID:
30597619
35.

A simplified radiosynthesis of [18 F]MK-6240 for tau PET imaging.

Hopewell R, Ross K, Kostikov A, Pascoal TA, Alberti T, Lacatus-Samoila M, Soucy JP, Bennacef I, Kobayashi E, Kang MS, Rosa-Neto P, Massarweh G.

J Labelled Comp Radiopharm. 2019 Feb;62(2):109-114. doi: 10.1002/jlcr.3695. Epub 2018 Dec 19.

PMID:
30426529
36.

Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer's Dementia.

Schilling LP, Pascoal TA, Zimmer ER, Mathotaarachchi S, Shin M, de Mello Rieder CR, Gauthier S, Palmini A, Rosa-Neto P; Alzheimer’s Disease Neuroimaging Initiative.

Mol Neurobiol. 2019 Jul;56(7):4916-4924. doi: 10.1007/s12035-018-1405-1. Epub 2018 Nov 9.

PMID:
30414086
37.

Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease.

Zhang H, Ng KP, Therriault J, Kang MS, Pascoal TA, Rosa-Neto P, Gauthier S; Alzheimer’s Disease Neuroimaging Initiative.

Transl Neurodegener. 2018 Sep 10;7:23. doi: 10.1186/s40035-018-0127-7. eCollection 2018.

38.

The influence of language and culture on cognitive assessment tools in the diagnosis of early cognitive impairment and dementia.

Ng KP, Chiew HJ, Lim L, Rosa-Neto P, Kandiah N, Gauthier S.

Expert Rev Neurother. 2018 Nov;18(11):859-869. doi: 10.1080/14737175.2018.1532792. Epub 2018 Oct 10.

PMID:
30286681
39.

Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.

Zhang H, Therriault J, Kang MS, Ng KP, Pascoal TA, Rosa-Neto P, Gauthier S; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2018 Aug 16;10(1):80. doi: 10.1186/s13195-018-0407-6.

40.

Optimal use of cholinergic drugs in Alzheimer's disease.

Gauthier S, Herrmann N, Rosa-Neto P.

Brain. 2018 Sep 1;141(9):e68. doi: 10.1093/brain/awy204. No abstract available.

PMID:
30084978
41.

In vivo quantification of neurofibrillary tangles with [18F]MK-6240.

Pascoal TA, Shin M, Kang MS, Chamoun M, Chartrand D, Mathotaarachchi S, Bennacef I, Therriault J, Ng KP, Hopewell R, Bouhachi R, Hsiao HH, Benedet AL, Soucy JP, Massarweh G, Gauthier S, Rosa-Neto P.

Alzheimers Res Ther. 2018 Jul 31;10(1):74. doi: 10.1186/s13195-018-0402-y.

42.

Reduced resting-state functional connectivity of the basolateral amygdala to the medial prefrontal cortex in preweaning rats exposed to chronic early-life stress.

Guadagno A, Kang MS, Devenyi GA, Mathieu AP, Rosa-Neto P, Chakravarty M, Walker CD.

Brain Struct Funct. 2018 Nov;223(8):3711-3729. doi: 10.1007/s00429-018-1720-3. Epub 2018 Jul 21.

PMID:
30032360
43.

PET/CT of Dementia.

Zukotynski K, Kuo PH, Mikulis D, Rosa-Neto P, Strafella AP, Subramaniam RM, Black SE.

AJR Am J Roentgenol. 2018 Aug;211(2):246-259. doi: 10.2214/AJR.18.19822. Epub 2018 Jun 27. Review.

PMID:
29949415
44.

Test-retest variability of [11 C]ABP688 estimates of metabotropic glutamate receptor subtype 5 availability in humans.

Smart K, Cox SML, Nagano-Saito A, Rosa-Neto P, Leyton M, Benkelfat C.

Synapse. 2018 Sep;72(9):e22041. doi: 10.1002/syn.22041. Epub 2018 Jul 20.

PMID:
29935121
45.

Impact of the biological definition of Alzheimer's disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology?

Gauthier S, Zhang H, Ng KP, Pascoal TA, Rosa-Neto P.

Transl Neurodegener. 2018 May 31;7:12. doi: 10.1186/s40035-018-0117-9. eCollection 2018. Review.

46.

Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis.

Meyer PF, Savard M, Poirier J, Labonté A, Rosa-Neto P, Weitz TM, Town T, Breitner J; Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD Research Group.

J Alzheimers Dis. 2018;63(2):577-590. doi: 10.3233/JAD-170887.

47.

Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment.

Gauthier S, Ng KP, Pascoal TA, Zhang H, Rosa-Neto P.

J Alzheimers Dis. 2018;64(s1):S23-S31. doi: 10.3233/JAD-179924. Review.

48.

Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.

Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS, Johnson SC, Breitner JCS, Poirier J; Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group.

JAMA Neurol. 2018 May 1;75(5):608-619. doi: 10.1001/jamaneurol.2017.5135.

49.

CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem.

Benedet AL, Yu L, Labbe A, Mathotaarachchi S, Pascoal TA, Shin M, Kang MS, Gauthier S, Rouleau GA, Poirier J, Bennett DA, Rosa-Neto P; Alzheimer's Disease Neuroimaging Initiative.

Neurol Genet. 2018 Jan 30;4(1):e216. doi: 10.1212/NXG.0000000000000216. eCollection 2018 Feb.

50.

Anosognosia predicts default mode network hypometabolism and clinical progression to dementia.

Therriault J, Ng KP, Pascoal TA, Mathotaarachchi S, Kang MS, Struyfs H, Shin M, Benedet AL, Walpola IC, Nair V, Gauthier S, Rosa-Neto P; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2018 Mar 13;90(11):e932-e939. doi: 10.1212/WNL.0000000000005120. Epub 2018 Feb 14.

Supplemental Content

Loading ...
Support Center